How Substack Creators Are Covering This Strange Markets Era
We closed out our New York live show on May 28 with a panel that featured three of our favorite Substackers: James van Geelen of Citrini Research, Sam Ro, founder of The TKer, and journalist Jasmine Sun. They've all been Odd Lots guests before, and we wanted to get them together to discuss how journalists and analysts are supposed to cover this incredibly strange and highly pressurized moment in markets. Not only has AI basically infected every corner of the world, the media included, but there's just so much news that it's sometimes hard to figure out what the focus should be. But James, Sam, and Jasmine have all found their own niches, and cover AI in a really unique way. This panel discussion debates how the media has covered fears over the AI bubble and the possibility of mass job loss, if people in Silicon Valley are scared about the future of society, if AI can really mimic a writer's voice and personality, and (if they can) how writers can hedge against that future.
Read more:Amazon in Talks to Sell Custom AI Chips in Bid to Undercut NvidiaAI Company Dream Triples Value to $3 Billion in Funding Round
Only http://Bloomberg.com subscribers can get the Odd Lots newsletter in their inbox each week, plus unlimited access to the site and app. Subscribe at bloomberg.com/subscriptions/oddlots
Subscribe to the Odd Lots NewsletterJoin the conversation: discord.gg/oddlots
See omnystudio.com/listener for privacy information.
James van Geelen on His Viral AI Doom Scenario
Something very unusual happened in the market in the last week of February. It sold off, in part, thanks to an article on Substack. James van Geelen is the founder of Citrini Research, which published a piece a week ago titled, “The 2028 Global Intelligence Crisis.” It was not written as a forecast of an imminent disaster, but rather as a scenario analysis in which AI capabilities lead to widespread white collar job losses, triggering a deep downturn, and a financial crisis. Nonetheless, the piece went extraordinary viral, gathering all kinds of responses from economists and research shops and even Citadel Securities. On this episode, we speak with James, the piece's co-author, about what Citrini Research actually is, why he wrote the piece, and why this is a scenario worth paying attention to, even if it's not the most likely outcome.
Read more:
Bank Shares Walloped by More AI and ‘Cockroach’ Credit Woes
Pentagon Casts Cloud of Doubt Over Anthropic’s AI Business
Only Bloomberg - Business News, Stock Markets, Finance, Breaking & World News subscribers can get the Odd Lots newsletter in their inbox each week, plus unlimited access to the site and app. Subscribe at bloomberg.com/subscriptions/oddlots
Subscribe to the Odd Lots Newsletter
Join the conversation: discord.gg/oddlots
See omnystudio.com/listener for privacy information.
James van Geelen on the Next Phase of the AI Buildout
Money has been flowing into the AI space, with billions pouring into GPU clusters, data centers, gas turbines, and the infrastructure needed to train and deploy bigger and bigger models. So what comes next? On this episode, we speak with James van Geelen, founder of Citrini Research. We talk to him about his latest field trip to one of OpenAI's new massive Stargate data centers in Abilene, Texas. We also discuss the increasingly complicated financing arrangements that are funding some of these mega projects and the energy needed to power them. Finally, we ask the question which everyone seems to be asking right now: is AI in a bubble?
Read more:OpenAI Valuation Reaches $500 Billion, Topping Musk’s SpaceXFOMO Builds as Alibaba Extends $250 Billion AI-Fueled Comeback
Only http://Bloomberg.com subscribers can get the Odd Lots newsletter in their inbox each week, plus unlimited access to the site and app. Subscribe at bloomberg.com/subscriptions/oddlots
See omnystudio.com/listener for privacy information.
James van Geelen on Thematic Investing Right Now
James van Geelen, founder of Citrini Research, scored big when he made his weight loss drug-related investments last year. He was also early into artificial intelligence investments, making bets on picks and shovels plays, like Nvidia. So what's interesting him right now? And how does a thematic investor grapple with uncertainty from things like the upcoming US election? We talk about the next stage of AI investing, constructing election-related portfolios, going long water, and more.
See omnystudio.com/listener for privacy information.
Lots More on What's Hot at JPM's Health Conference
For anyone interested in investing in the health-care space, JPMorgan's annual Health Care Conference has become one of the most important events of the year. We were not able to get to San Francisco this year, but one of our favorite Odd Lots guests, James van Geelen of CitriniResearch.com, was in attendance. He called into this week's episode of Lots More to tell us what the leading players in health care and medical technology are buzzing about right now — and he confirms that AI and GLP-1 weight loss drugs are at the top of everyone's mind."
See omnystudio.com/listener for privacy information.
Here's How the New Weight Loss Drugs Could Change Everything
There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI.
See omnystudio.com/listener for privacy information.